Table 4.
Treatment success rates
| Week/Outcome | Total N = 68% (n) [95% CI] | Microadenomas N = 8% (n) [95% CI]* | Macroadenomas N = 60% (n) [95% CI] |
|---|---|---|---|
| Week 24 | |||
| Overall treatment success | 50·0 (34) | 100·0 (8) | 43·3 (26) |
| [37·3, 62·7] | [63·1, 100·0] | [29·9, 56·8] | |
| Total success | 26·5 (18) | 75·0 (6) | 20·0 (12) |
| [15·2, 37·8] | [34·9, 96·8] | [9·0, 31·0] | |
| Partial success | 23·5 (16) | 25·0 (2) | 23·3 (14) |
| [12·6, 34·4] | [3·2, 65·1] | [11·7, 35·0] | |
| Week 48 | |||
| Overall treatment success | 47·1 (32) | 75·0 (6) | 43·3 (26) |
| [34·4, 59·7] | [34·9, 96·8] | [29·9, 56·8] | |
| Total success | 25·0 (17) | 37·5 (3) | 23·3 (14) |
| [13·9, 36·1] | [8·5, 75·5] | [11·7, 35·0] | |
| Partial success | 22·1 (15) | 37·5 (3) | 20·0 (12) |
| [11·4, 32·7] | [8·5, 75·5] | [9·0, 31·0] | |
Total success: mean of 2-h GH profile ≤ 2·5 µg/l and IGF-I levels within laboratory normal range.
Partial success: (1) mean of 2-h GH profile > 2·5 and ≤ 5·0 µg/l and either a decrease in IGF-I of at least 50% in comparison to baseline levels or IGF-I levels within laboratory normal range, or (2) mean of 2-h GH profile ≤ 2·5 µg/l and a decrease in IGF-I of at least 50% in comparison to baseline levels and IGF-I levels outside normal range.
*
Using exact calculation method because of the small number of subjects.